Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin

Objective To systematically estimate and compare the effectiveness and cost-effectiveness of the glucagon-like peptide-1 receptor agonists (GLP-1RAs) approved in China and to quantify the relationship between the burden of diabetic comorbidities and glycosylated hemoglobin (HbA1c) or body mass index (BMI). Methods To estimate the costs (US dollars, USD) and quality-adjusted life years (QALY) for six GLP-1RAs (exenatide, loxenatide, lixisenatide, dulaglutide, semaglutide, and liraglutide) combined with metformin in the treatment of patients with type 2 diabetes mellitus (T2DM) which is inadequately controlled on metformin from the Chinese healthcare system perspective, a discrete event microsimulation cost-effectiveness model based on the Chinese Hong Kong Integrated Modeling and Evaluation (CHIME) simulation model was developed. A cohort of 30,000 Chinese patients was established, and one-way sensitivity analysis and probabilistic sensitivity analysis (PSA) with 50,000 iterations were conducted considering parameter uncertainty. Scenario analysis was conducted considering the impacts of research time limits. A network meta-analysis was conducted to compare the effects of six GLP-1RAs on HbA1c, BMI, systolic blood pressure, and diastolic blood pressure. The incremental net monetary benefit (INMB) between therapies was used to evaluate the cost-effectiveness. China’s per capita GDP in 2021 was used as the willingness-to-pay threshold. A generalized linear model was used to quantify the relationship between the burden of diabetic comorbidities and HbA1c or BMI. Results During a lifetime, the cost for a patient ranged from USD 42,092 with loxenatide to USD 47,026 with liraglutide, while the QALY gained ranged from 12.50 with dulaglutide to 12.65 with loxenatide. Compared to exenatide, the INMB of each drug from highest to lowest were: loxenatide (USD 1,124), dulaglutide (USD −1,418), lixisenatide (USD −1,713), semaglutide (USD −4,298), and liraglutide (USD −4,672). Loxenatide was better than the other GLP-1RAs in the base-case analysis. Sensitivity and scenario analysis results were consistent with the base-case analysis. Overall, the price of GLP-1RAs most affected the results. Medications with effective control of HbA1c or BMI were associated with a significantly smaller disease burden ( p < 0.05). Conclusion Loxenatide combined with metformin was identified as the most economical choice, while the long-term health benefits of patients taking the six GLP-1RAs are approximate

Cost effectiveness · Cost-effectiveness analysis · Diabetes mellitus · Dulaglutide · Insulin · Liraglutide · Metformin · Type 2 diabetes · Type 2 Diabetes Mellitus · Diabetes Treatment and Management · Diabetes, Cardiovascular Risks, and Lipoproteins · Medication Adherence and Compliance · Medicine · Endocrinology · Internal Medicine

• Prevalence and Treatment of Diabetes in China, 2013-2018

  Limin Wang, Wen Peng et al.•JAMA•2021

  Incluir item

• The Cost-Effectiveness Analysis of Self-Efficacy-Focused Structured Education Program for Patients With Type 2 Diabetes Mellitus in Mainland China Setting

  Open Access•Xinjun Jiang, Hua Jiang et al.•Frontiers in Public Health•2021

  Incluir item

• Omicron Covid-19 variant outcomes and vaccination in non-severe and non-critical patients at admission

  Open Access•Hong Zhao, Wenyi Ye et al.•Frontiers in Public Health•2023

  Incluir item

• Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China

  Open Access•Mingye Zhao, Xingming Pan et al.•Frontiers in Public Health•2022

  Incluir item

• Prevalence of overweight and obesity in Mozambique in 2005 and 2015

  Open Access•Fernando Fontes, Albertino Damasceno et al.•Public Health Nutrition•2019

  Incluir item